178 completed, 49 recruiting, 33 unknown, 28 terminated. 330 Phase 1, 167 Phase 2.
Follow Retinal Degeneration: new trials by email Literature Review of Retinal Degeneration trials Research Report on Retinal Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Evaluation Study of Pitavastatin PLGA Nano-particle for Retinitis Pigmentosa ULREA-PVS-NP - Retinitis Pigmentosa (RP) | Phase 1 | Recruiting | Kyushu University | 21 | 2026-10-01 | 2026-10-07 |
| Evaluation of PAN-90806 Eye Drops in Healthy Subjects PAN-90806 Ophthalmic Solution, Vehicle Ophthalmic Solution - Wet Age Related Macular Degeneration, Neovascular (Wet) Age-Related Macular Degeneration | Phase 1 | Not yet recruiting | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | 20 | 2026-09-30 | 2026-08-14 |
| A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration BRX011, Placebo - Geographic Atrophy | Phase 1 / Phase 2 | Recruiting | Biojiva LLC | 152 | 2026-09-29 | 2026-09-23 |
| Phase I/II Open-Label Trial of UGX202 for Advanced Retinitis Pigmentosa UGX202 Injection - Retinitis Pigmentosa (RP) | Phase 1 | Not yet recruiting | Suzhou UgeneX Therapeutics Co., Ltd. | 12 | 2026-09-28 | 2026-10-02 |
| A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants CITY-RBP4, Placebo - Stargardt Disease 1, STGD1 | Phase 1 | Recruiting | City Therapeutics | 48 | 2026-09-01 | 2026-09-23 |
| First in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD) BETA-TT8 ophthalmic gel 3.8% w/v - Neovascular (Wet) Age-Related Macular Degeneration | Phase 1 / Phase 2 | Not yet recruiting | Filamon LTD | 24 | 2026-09-01 | 2026-09-18 |
| A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions ASP2020 - Stargardt Disease, Stargardt Macular Dystrophy | Phase 1 | Recruiting | Astellas Institute for Regenerative Medicine | 30 | 2026-08-14 | 2026-10-28 |
| 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients 9-cis beta-Carotene-rich extract of Dunaliella alga, Placebo Corn Oil - Retinitis Pigmentosa | Phase 1 / Phase 2 | Enrolling by invitation | Sheba Medical Center | 41 | 2026-07-26 | 2026-07-27 |
| A First-In-Human Study of ARO-033 in Adult Participants ARO-033, Placebo - Age-related Macular Degeneration | Phase 1 | Recruiting | Arrowhead Pharmaceuticals | 84 | 2026-06-25 | 2026-09-15 |
| Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection) ZM-02 (low dose), ZM-02 (high dose), ZM-02 (selected dose) - Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Not yet recruiting | Zhongmou Therapeutics | 21 | 2026-06-25 | 2026-04-13 |
| A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy TO-O-1007 (low-dose), TO-O-1007 (high-dose), Sham injection - Geographic Atrophy Due to Age-Related Macular Degeneration | Phase 1 / Phase 2 | Recruiting | Theratocular Biotek Co. | 31 | 2026-06-02 | 2026-06-25 |
| Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration EYC-0305 - Neovascular (Wet) Age-Related Macular Degeneration | Phase 1 / Phase 2 | Recruiting | Eyconis INC. | 30 | 2026-05-19 | 2026-10-09 |
| A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa DSP-3077 Retinal Sheet Cohort 1, DSP-3077 Retinal Sheet Cohort 2, DSP-3077 Retinal Sheet Cohort 3 - Retinitis Pigmentosa | Phase 1 / Phase 2 | Recruiting | Sumitomo Pharma America, Inc. | 12 | 2026-04-16 | 2026-04-17 |
| Phase 1 Study of C.001 in Retinal Degeneration Injection - Geographic Atrophy, Stargardt Disease | Phase 1 | Recruiting | Cellio Therapeutics Inc | 15 | 2026-04-07 | 2026-11-03 |
| A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP) Phase 1b/2: Cohort 1 - OCT-980 Tablet, Phase 1b/2: Cohort 2 - OCT-980 Tablet, Phase 1b/2: Cohort 3 - OCT-980 Tablet - Retinitis Pigmentosa | Phase 1 / Phase 2 | Recruiting | Octant, Inc. | 18 | 2026-03-10 | 2026-09-24 |
| The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa Alga Dunaliella Bardawil powder, Placebo:Starch - Retinitis Pigmentosa | Phase 1 / Phase 2 | Not yet recruiting | Sheba Medical Center | 30 | 2026-03-01 | 2025-10-06 |
| A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses ABF-101, Placebo - Age Related Macular Degeneration (ARMD), AMD - Age-Related Macular Degeneration | Phase 1 | Recruiting | Aptabio Therapeutics, Inc. | 68 | 2026-02-01 | 2026-02-06 |
| Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease RTx-021 - Stargardt Disease | Phase 1 / Phase 2 | Recruiting | Ray Therapeutics, Inc. | 18 | 2026-01-28 | 2026-04-15 |
| Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants Pozelimab - Geographic Atrophy (GA) | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 54 | 2026-01-19 | 2026-08-05 |
| A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD BS01, Sham procedure control - Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD) | Phase 1 / Phase 2 | Recruiting | Bionic Sight LLC | 40 | 2026-01-08 | 2026-01-23 |
Showing 20 of 330. Sign in to see all of them.
Macular Degeneration (164) · Retinitis Pigmentosa (66) · Macular Edema (59) · Geographic Atrophy (37) · Retinal Diseases (34) · Eye Diseases (28) · Choroidal Neovascularization (24) · Stargardt Disease (22) · Retinal Vein Occlusion (16) · Diabetic Retinopathy (14) · Retinal Dystrophies (12) · Uveitis (12) · Cone-Rod Dystrophies (9) · Diabetes Mellitus (9)
Eye Diseases (302) · Retinal Diseases (296) · Eye Diseases, Hereditary (110) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (101) · Genetic Diseases, Inborn (99) · Macular Degeneration (87) · Retinal Dystrophies (67) · Pathological Conditions, Signs and Symptoms (50) · Uveal Diseases (41) · Pathologic Processes (34) · Cardiovascular Diseases (33) · Vascular Diseases (32) · Metaplasia (29) · Choroid Diseases (28)
Ranibizumab (30) · aflibercept (10) · Triamcinolone Acetonide (6) · salicylhydroxamic acid (5) · Minocycline (4) · Bevacizumab (3) · Dexamethasone (3) · Lutein (3) · Sirolimus (3) · Triamcinolone (3) · Vitamin E (3) · interferon gamma-1b (3) · pazopanib (3) · retinol acetate (3) · AXT107 (2)
National Eye Institute (NEI) (29) · GlaxoSmithKline (7) · Johns Hopkins University (6) · Allergan (5) · Astellas Institute for Regenerative Medicine (5) · Hoffmann-La Roche (5) · University of Sao Paulo (5) · Chengdu Origen Biotechnology Co., Ltd. (4) · Novartis Pharmaceuticals (4) · Vitreous -Retina- Macula Consultants of New York (4) · Alcon Research (3) · Boehringer Ingelheim (3) · Genentech, Inc. (3) · PYC Therapeutics (3) · Pfizer (3)
United States (217) · China (22) · United Kingdom (21) · Australia (18) · Israel (12) · France (10) · Brazil (9) · Puerto Rico (7) · Canada (6) · Germany (6) · Italy (4) · Japan (4) · Netherlands (4) · New Zealand (4) · India (3)
Rubens C Siqueira, MD,PhD (3) · Sushanta Mallick (3) · Amir Shojaei, PhD (2) · Arshad Khanani, MD (2) · Catherine A Cukras, M.D. (2) · Cathy Sutherland (2) · David M Brown, MD (2) · Emily Y Chew, M.D. (2) · Farzin Forooghian, MD (2)
PMID 30194931, PMID 32573764, PMID 22281388, PMID 24113783, PMID 25458728, PMID 36912792, PMID 39207600, PMID 40547876, PMID 16759390, PMID 16896916, PMID 17342504, PMID 17963111, PMID 18321465, PMID 18441371, PMID 19906082, PMID 20169166, PMID 20609706, PMID 20688744, PMID 21498606, PMID 21546089, PMID 21555610, PMID 22491916, PMID 22775078, PMID 22828504, PMID 22895887, PMID 23049090, PMID 23316779, PMID 23361508, PMID 23548622, PMID 23689994, PMID 24053892, PMID 24439297, PMID 24705452, PMID 24896137, PMID 25001321, PMID 25030840, PMID 25376617, PMID 25491299, PMID 25525171, PMID 25677668, PMID 25744334, PMID 26427420, PMID 26431823, PMID 26448901, PMID 26605849, PMID 26656277, PMID 26857842, PMID 27403996, PMID 27710144, PMID 27730010
2025 (3), 2016 (2), 2017 (2), 2018 (2), 2009 (1), 2014 (1)